Search
George Underwood / PharmaTimes
2 min read
Top three therapy areas dominate pipelines
The world's top three therapy areas accounted for 68 percent of the overall pharmaceutical industry pipeline as of Q1 2016, according to...
by Selina McKee / PharmaTimes online
2 min read
GSK teams up with Google on bioelectronic medicines
GlaxoSmithKline is teaming up with Google's parent company Alphabet to create a new company focused on developing bioelectronic...
by Beth Snyder Bulik / FiercePharma
2 min read
Value-based care necessitates big changes for pharma marketers, says digital pharma agency
Much has been discussed, and some dismissed, when it comes to value-based care in the pharma industry. However, no one can deny that the...
by Ari Altstedter and Manish Modi / Bloomberg
3 min read
India’s Drug Approvals Near Record Despite FDA Inspection Blitz
Even as the FDA has increased scrutiny of India, it’s been approving generic drug applications from the country’s firms at a record pace....
By David Schultz on www.slate.com / medical
2 min read
With a Name Like Xalkori
New drug names aren’t just bizarre—they’re dangerous. What would Don Draper make of Xalkori? Pfizer’s lung cancer drug, released in 2011,...
By Rebecca Boyle, Popular science, april 2013
3 min read
How does a drug get its name?
Street names aside, who comes up with crazy non-words like Zyrtec, Tenofovir and Xeljanz? Say it with me: Xeljanz. OK, at least try and...
Anthony J Cordato of Cordato Partners, Australia
5 min read
How the Nurofen Specific Pain Range marketing strategy was undone as misleading by the Australian AC
It was a brilliant marketing strategy … instead of marketing the fast-acting Nurofen for pain relief as one product effective for a range...
By Bronwen Morgan
1 min read
Pharma product launch optimisation tool
Vivisum has launched Brand Builder, a solution that provides strategic market insight for pharmaceutical brands. Brand Builder combines...
by FiercePharma editor
3 min read
As biosims win nods in Europe and India, debate over naming rights heats up
From www.fiercepharma.com Drugmakers, biotechs and their generic rivals are squabbling over the names that will be assigned to...
Franki Webb in iPPro interviews Ira Levy
5 min read
The FDA way
Ira Levy of Goodwin Procter discusses the FDA regulation for drug names and how companies can reduce their chances of rejection. What is...